Influence of Type 2 Diabetes in the Association of
PNPLA3 p.I148M
TM6SF2 p.E167K
advanced fibrosis
homeostatic model assessment for insulin resistance (HOMA-IR)
nonalcoholic steatohepatitis (NASH)
type 2 diabetes (T2D)
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
29
03
2022
revised:
22
04
2022
accepted:
26
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Nonalcoholic steatohepatitis (NASH) is a leading cause of cirrhosis in western countries. Insulin resistance (IR), type 2 diabetes (T2D), and the polymorphisms patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 and transmembrane 6 superfamily member 2 (TM6SF2) rs58542926 are independent risk factors of NASH. Nevertheless, little is known about the interaction between IR and T2D with these polymorphisms in the pathogenesis of NASH and the development of advanced fibrosis. Thus, our study aimed to investigate this relationship. This is a cross-sectional study including NASH patients diagnosed by liver biopsy, at the Vall d’Hebron University Hospital. A total of 140 patients were included (93 T2D, 47 non-T2D). T2D (OR = 4.67; 95%CI 2.13−10.20; p < 0.001), PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms (OR = 3.94; 95%CI 1.63−9.54; p = 0.002) were independently related with advanced liver fibrosis. T2D increased the risk of advance fibrosis on top of the two polymorphisms (OR = 14.69; 95%CI 3.03−77.35; p = 0.001 for PNPLA3 rs738409 and OR = 11.45; 95%CI 3.16−41.55; p < 0.001 for TM6SF2 rs58542926). In non-T2D patients, the IR (HOMA-IR ≥ 5.2, OR = 14.33; 95%CI 2.14−18.66; p = 0.014) increased the risk of advanced fibrosis when the polymorphisms were present (OR = 19.04; 95%CI 1.71−650.84; p = 0.042). The T2D and IR status increase the risk of advanced fibrosis in patients with NASH carrying the PNPLA3 rs738409 and/or TM6SF2 rs58542926 polymorphisms, respectively.
Identifiants
pubmed: 35625751
pii: biomedicines10051015
doi: 10.3390/biomedicines10051015
pmc: PMC9139123
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Hypertens Rep. 2018 Feb 26;20(2):12
pubmed: 29480368
J Hepatol. 2018 Feb;68(2):268-279
pubmed: 29122391
Diabetes Care. 2021 Feb;44(2):399-406
pubmed: 33355256
Hepatol Commun. 2017 Dec 27;2(2):199-210
pubmed: 29404527
Nat Genet. 2008 Dec;40(12):1461-5
pubmed: 18820647
Diabetologia. 2017 Jul;60(7):1218-1222
pubmed: 28352941
Medicine (Baltimore). 2019 Feb;98(7):e14324
pubmed: 30762732
BBA Clin. 2014 Sep 20;3:141-5
pubmed: 26675585
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Front Genet. 2016 Aug 02;7:140
pubmed: 27532011
Acta Diabetol. 2016 Apr;53(2):251-60
pubmed: 26070771
J Hepatol. 2020 Sep;73(3):505-515
pubmed: 32298765
J Lipid Res. 2017 Jan;58(1):247-255
pubmed: 27836992
Aliment Pharmacol Ther. 2018 May;47(10):1387-1396
pubmed: 29577364
World J Gastroenterol. 2016 Aug 7;22(29):6742-56
pubmed: 27547017
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2017 May;65(5):1557-1565
pubmed: 28130788
Transplantation. 2020 Mar;104(3):526-534
pubmed: 31356578
JAMA. 2020 Mar 24;323(12):1175-1183
pubmed: 32207804
World J Clin Cases. 2018 Aug 16;6(8):167-175
pubmed: 30148144
Clin Gastroenterol Hepatol. 2019 Oct;17(11):2310-2319.e6
pubmed: 30708111
Can J Physiol Pharmacol. 2021 Jun;99(6):599-608
pubmed: 33064960
Biotechniques. 2001 Nov;31(5):1106-16, 1118, 1120-1
pubmed: 11730017
Endocr Connect. 2021 Oct 07;10(10):R240-R247
pubmed: 34486981
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Rev Cardiovasc Med. 2021 Sep 24;22(3):755-768
pubmed: 34565074
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Clin Liver Dis. 2016 May;20(2):215-24
pubmed: 27063265
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Hepatology. 2015 Feb;61(2):506-14
pubmed: 25251399
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
PLoS One. 2017 Jun 1;12(6):e0178473
pubmed: 28570615
Hepatology. 2020 Sep;72(3):845-856
pubmed: 32190914
Antioxidants (Basel). 2021 Feb 10;10(2):
pubmed: 33578702
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42
pubmed: 27729660
Diabetes Care. 2015 Jul;38(7):1347-55
pubmed: 25887357
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Hepatol. 2019 Oct;71(4):793-801
pubmed: 31279902
J Nutr Biochem. 2021 Sep;95:108778
pubmed: 34004342
BMC Endocr Disord. 2013 Oct 16;13:47
pubmed: 24131857
Diabetes. 2016 Jun;65(6):1511-20
pubmed: 26861781
Nat Genet. 2014 Apr;46(4):352-6
pubmed: 24531328
World J Hepatol. 2020 Oct 27;12(10):792-806
pubmed: 33200017
Hepatology. 2010 Apr;51(4):1209-17
pubmed: 20373368
Am J Gastroenterol. 2010 Feb;105(2):336-44
pubmed: 19861959
Ann Hepatol. 2020 Sep - Oct;19(5):472-481
pubmed: 32682086
Front Pharmacol. 2020 Jan 08;10:1413
pubmed: 31969816
Cells. 2020 Nov 11;9(11):
pubmed: 33187255
J Hepatol. 2022 Mar;76(3):526-535
pubmed: 34710482
Clin Gastroenterol Hepatol. 2020 Oct;18(11):2592-2599.e10
pubmed: 32062042
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes Metab J. 2019 Oct;43(5):700-710
pubmed: 31694082
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
BMC Cancer. 2019 Nov 21;19(1):1128
pubmed: 31752753
Hepatol Commun. 2019 Apr 18;3(7):894-907
pubmed: 31334442